Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial
- PMID: 38971163
- DOI: 10.1016/S2468-1253(24)00130-4
Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial
Conflict of interest statement
NNS receives teaching and speaking honoraria from AstraZeneca and Total Health Conferencing. The Medical College of Wisconsin, WAH's institution, holds patent 63/483,252 (“Monitoring organ morphology for radiation treatment delivery using ultrasound”). WAH receives research and travel support from Elekta; is Vice Chair of the clinical steering committee for the MR-Linac Consortium; receives consulting fees from Aktis Oncology; and holds stock in Sonoptima, which focuses on developing patent 63/483,252. JMW declares no competing interests.
Comment in
-
Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial: Authors' reply.Lancet Gastroenterol Hepatol. 2024 Aug;9(8):687-688. doi: 10.1016/S2468-1253(24)00162-6. Lancet Gastroenterol Hepatol. 2024. PMID: 38971162 No abstract available.
Comment on
-
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial.Lancet Gastroenterol Hepatol. 2024 May;9(5):448-459. doi: 10.1016/S2468-1253(24)00017-7. Epub 2024 Mar 19. Lancet Gastroenterol Hepatol. 2024. PMID: 38513683 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
